Rituximab Sc and Iv Plus Chop Show Similar Efficacy and Safety in the Randomised Mabease Study in First-Line DLBCL

Hematological Oncology - United Kingdom
doi 10.1002/hon.2438_46
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Efficacy and Safety of First-Line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma

JAMA Oncology
Cancer ResearchOncology
2018English

Safety Analysis of Australasian Leukaemia & Lymphoma Group Nhl29: A Phase Ii Study of Ibrutinib, Rituximab and Mini-Chop in Very Elderly Patients With Newly Diagnosed DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study

Journal of Immunology Research
MedicineAllergyImmunology
2018English

Time and Motion Study for Rituximab Sc vs Iv in Colombian Patients With Non-Hodgkin Lymphoma

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2013English

Polarix: A Phase 3 Study of Polatuzumab Vedotin (Pola) Plus R-CHP Versus R-Chop in Patients (Pts) With Untreated DLBCL

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

OP0142 Rituximab in Systemic Sclerosis : Safety and Efficacy Data From the Eustar Network

2018English

Safety and Efficacy of Venetoclax Combined With Rituximab, Ifosfamide, Carboplatin and Etoposide (Vicer) for Treatment of Relapsed Dlbcl: Final Results From the Phase 1trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Dose Finding Study to Assess Safety, Pk and Efficacy of Fimepinostat (Cudc-907) With Venetoclax or Rituximab Plus Bendamustine in Patients With Relapsed/Refractory Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy